March 2, 2009. Last year, the U.S. Supreme Court ruled in Riegel v. Medtronic, Inc. that medical devices makers are shielded from personal injury lawsuits, if their defective or unsafe product was approved by the Food and Drug Administration’s (FDA) pre-market approval (PMA) process.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony at FDA Science Board Meeting on the Use of Bisphenol A in Food Containers
February 24, 2009. NCHR was very pleased with the Science Board’s criticisms of the FDA Draft report on BPA and were disappointed that the FDA has not acknowledged the bottom line criticism: that the FDA drew conclusions about the safety of BPA that were not based on sound science, and that no conclusions can be made about safety until the FDA pays attention to the best studies conducted by federally funded scientists and designs appropriate follow-up research.
Read More »Testimony Regarding Food Safety Before the USDA Dietary Guidelines Advisory Committee
January 29, 2009. Methylmercury in Fish. In 2005, this Advisory Committee’s Dietary Guidelines Report included information about the risks of methylmercury in fish consumed by pregnant and nursing women and young children.
Read More »Testimony at the FDA Advisory Panel Meeting on Dermal Fillers
November 8, 2008. The FDA’s summary regarding dermal fillers is consistent with articles published in medical journals and calls we have received by patients — some people are having serious, unexpected adverse reactions.
Read More »Testimony at FDA Science Board Meeting on Bisphenol A for Use in Food Contact Applications
October 31, 2008. The FDA needs to conduct new studies of a much larger and more representative sample of infant formula containers.
Read More »